drugset
drugset / Trial / NCT04656041

Folfox+Irinotecan+Chemort In Esophageal Cancer

NCT04656041 ↗

Phase 2 Recruiting 40 enrolled Massachusetts General Hospital Ipsen · collab
NaSingle-groupOpen-labelTreatment

Summary

In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan

Timeline

Start
2021-06-29
Primary completion
2024-04-30
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule — Intravenous
Background Carboplatin Small molecule — —
Background Leucovorin Small molecule — Intravenous
Background Oxaliplatin Small molecule — Intravenous
Background Paclitaxel Small molecule — —
Background fluorouracil Small molecule — Intravenous

Indications

gastroesophageal cancer gastroesophageal junction adenocarcinoma